Beyond a synthetic lethal pair: The atorvastatin-gefitinib combination as a testable model for cross-pillar therapy in colorectal cancer

Abstract

We read with great interest the article by Huang and Ma which reported a synthetic lethal interaction between 3-hydroxy-3-methylglutaryl-CoA reductase and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta in colorectal cancer (CRC) using atorvastatin and gefitinib. This opinion review proposes an extended conceptual framework to interpret the synergy reported therein. We argue that this treatment may involve a cross-pillar interaction between sustained proliferative signaling, targeted by the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib, and metabolic reprogramming, affected by cholesterol synthesis blockade through atorvastatin. This two-pronged pressure may limit the adaptive capacity of tumor cells and help explain the anti-proliferative and pro-autophagy effects reported. The AMP-activated protein kinase-sterol regulatory element-binding protein 1 node identified in the original study may serve as an integrative hub linking these pillars. Accumulating preclinical evidence from various cancers suggests that sterol regulatory element-binding protein family members can connect oncogenic signaling and metabolic adaptation. However, available data remain mainly from in vitro and xenograft models. This study may provide insight into a CRC-centered, testable cross-pillar framework rather than a broadly validated therapeutic paradigm. Future studies should assess patient-derived models, predictive biomarkers, safety, efficacy and the context-dependence of this strategy in CRC.

Key Words: Colorectal cancer; Synthetic lethality; Drug repurposing; Combination therapy; Cancer hallmarks; Sterol regulatory element-binding protein

Core Tip: The combination of atorvastatin and gefitinib may offer a colorectal cancer-centered cross-pillar therapeutic model that links complementary cancer hallmarks. A framework centered on sterol regulatory element-binding protein family members as integrative hubs linking oncogenic signaling to metabolic reprogramming may provide a mechanistic basis to rationalize the design of synergistic combination therapies. Although this testable model is currently supported mainly by preclinical evidence, it requires robust validation by multifactorial studies, patient-derived models, and biomarker-driven clinical trials.

INTRODUCTION

We are intrigued by Huang and Ma’s report[1] of a synthetic lethal interaction between 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta in colorectal cancer (CRC). According to the authors, combination therapy using atorvastatin, which inhibits HMGCR, and gefitinib, which inhibits epidermal growth factor receptor (EGFR) tyrosine kinase signaling and may affect downstream phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)-related signaling, may reduce tumor proliferation and metastasis through AMP-activated protein kinase (AMPK)-sterol regulatory element-binding protein 1 (SREBP1) pathway blockade. This study can be considered a notable drug repurposing case.

We propose a framework that may help clarify the significant synergy observed and explore how this efficacy might be enhanced. Moreover, apart from the discovery of a new synthetic lethal pair, this combination may act as a testable therapeutic model which simultaneously targets different, non-redundant “cancer survival pillars”[2]. Sustained proliferative signaling is considered one of the major drivers of cancer development. Pathways such as EGFR-PI3K-AKT promote excessive proliferation while also allowing cells to evade apoptosis[3].

Compounds that inhibit this pillar, such as gefitinib, have been shown to have clinical efficacy in selected tumor contexts, but monotherapy usually fails due to redundancy of pathways or compensatory activation of alternative survival pathways[3,4]. Metabolic reprogramming, notably the abnormal production of cholesterol by way of the mevalonate pathway, has been recognized as an equally important dependency as it provides membrane components and lipid rafts for oncogenic signaling[5]. The above pillars do not operate in isolation; they are engaged in extensive bidirectional crosstalk, e.g. PI3K/AKT-mediated regulation of SREBP transcription factors that control lipid biosynthesis[5]. The dependency of both pillars may create a therapeutic vulnerability such that dual perturbation may exploit synthetic lethal interactions to enhance antitumor effects and limit compensatory resistance[6,7].

FROM OBSERVATION TO CONCEPTUALIZATION: THE CROSS-PILLAR HYPOTHESIS

Gefitinib’s actions on EGFR tyrosine kinase signaling impair sustained proliferative signaling pillars, while phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta or PI3K/AKT-related vulnerability should be interpreted as downstream, pathway-level and context-dependent biology rather than as direct PI3Kδ inhibition by gefitinib. Atorvastatin disrupts cellular metabolic programming by blocking cholesterol synthesis. The cross-pillar intervention may be responsible for the reported synergy. The cancer cells are forced to simultaneously compensate for a weakened primary growth signal and a disrupted metabolic foundation.

The rationale for combining statins with targeted therapies is not limited to CRC, although most of the available evidence remains preclinical and should be considered supportive and indirect rather than direct validation in CRC[8-10]. In EGFR-mutant non-small cell lung cancer (NSCLC), atorvastatin synergizes with EGFR tyrosine kinase inhibitors (TKIs), specifically gefitinib or osimertinib, causing a significant anti-tumor effect according to Luo et al[3]. The combination of atorvastatin with gefitinib yielded an approximate tumor shrinkage of 89% in HCC827 xenografts in their animal experiments, while gefitinib alone afforded 68% and atorvastatin 49%[3]. The study also found that low-density lipoprotein receptor expression is upregulated by EGFR signaling through an SREBP1-dependent pathway, demonstrating a mechanistic connection between these two pillars[3].

Fiala et al[8] assessed 67 patients with advanced-stage NSCLC and Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations who were treated with erlotinib or gefitinib. According to this study, patients receiving a combination treatment of EGFR-TKI and statin had a significantly greater progression-free survival (2.0 months vs 1.0 months; P = 0.025). In addition, there was a trend toward improved overall survival (14.0 months vs 5.4 months; P = 0.130) with the combination treatment[8]. This provides supportive clinical observation suggesting that incorporating a statin into EGFR-TKI treatment may enhance efficacy in some settings, especially in the difficult KRAS mutant population that usually has a poor response to EGFR inhibitors. However, it should not be interpreted as direct clinical validation of the atorvastatin-gefitinib strategy in CRC.

MECHANISTIC CONVERGENCE AND PILLAR INTERPLAY

This convergence on the AMPK-SREBP1 node supports this model, as this node is a major integrator of cellular energy status and growth signals (Figure 1). The links between the pillars do not run parallel to each other. Rasmi et al[5] reported a significant crosstalk of SREBP2 with various aberrant signaling pathways such as PI3K/AKT/mechanistic target of rapamycin complex 1 (mTORC1), tumor protein p53, transforming growth factor-β, c-Myc, and Hippo. All these pathways have been reported to promote tumors. The SREBP family of transcription factors is important for determining how signaling from cancerous growth modifies metabolism[5,11,12].

Figure 1 Proposed AMP-activated protein kinase-sterol regulatory element-binding protein 1-centered model of the atorvastatin-gefitinib combination in colorectal cancer. Gefitinib is shown as an epidermal growth factor receptor tyrosine kinase inhibitor; phosphatidylinositol 3-kinase/protein kinase B- or phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta-related elements should be interpreted as downstream and context-dependent pathway components rather than direct pharmacological targets of gefitinib. EGFR: Epidermal growth factor receptor; PI3K: Phosphatidylinositol 3-kinase; AKT: Protein kinase B; AMPK: AMP-activated protein kinase; SREBP1: Sterol regulatory element-binding protein 1; HMGCR: 3-hydroxy-3-methylglutaryl-CoA reductase. Created with MedPeer (medpeer.cn).

The study by Zhang et al[9] on CRC liver metastasis models provided evidence for this axis. The study demonstrated that PI3K/AKT/mTOR signaling pathway activation directly upregulates SREBP2 activity which is the master transcription factor for cholesterol biosynthesis. This reflects a biological axis in which the signaling pillar has an upstream regulatory effect on the metabolic pillar. Thus, the combination of gefitinib (which inhibits EGFR tyrosine kinase signaling and may modulate downstream PI3K/AKT-related pathway states) and atorvastatin (which inhibits HMGCR) represents a dual-level intervention at this axis. On the one hand, the regulatory signal is inhibited; on the other hand, the metabolic output of the cancer cell is constrained.

Notably, SREBP was recently shown to have roles beyond lipid metabolism. Zhong et al[10] have discovered that SREBP1 does not stimulate glucose uptake by activating glycolytic enzymes; rather, it does so by inducing the expression of glucose transporters glucose transporter 3 and glucose transporter 6, which enables tumor resistance to lysosome inhibition. This study shows that SREBP1 may serve as a regulator linking signaling pathways with lipid and glucose metabolism, and disrupting this SREBP1-glucose uptake feedforward loop produces a synergistic anticancer effect[10]. SREBP is a candidate integrative hub. It coordinates multiple aspects of metabolism. These include lipogenesis, cholesterol metabolism, and lysosomal lipid catabolism. Therefore, this finding further supports the rationale for studying SREBP-related targeting[13-15]. Although this evidence is not CRC-specific, it supports the broader biological plausibility of SREBP-centered signaling-metabolism crosstalk.

CONSTRAINING RESISTANCE THROUGH CROSS-PILLAR TARGETING

The cross-pillar strategy may help constrain adaptive drug resistance in selected settings. According to Chen et al[4], atorvastatin attenuates resistance to gefitinib in NSCLC cells with KRAS mutation. It offers an explanation for testing this combination in hard-to-treat populations. This preclinical finding is consistent with the clinical findings of Fiala et al[8] and collectively suggests that disruption of cholesterol synthesis by statins may re-sensitize some resistant tumors to EGFR inhibition[16,17].

A similar cross-pillar logic has also been observed in hematological cancer models. According to Zhu et al[6], blocking either SREBP signaling or the downstream target HMGCR with fatostatin or simvastatin reduced the proliferation of B-cell lymphoma cells. Notably, the lymphoma cells they studied activated the mTORC1-phosphorylated ribosomal protein S6 pathway in response to statin treatment as a compensatory survival mechanism. The combination of a low-dose statin with the mTOR inhibitor rapamycin produced a strong synergy and significantly inhibited the proliferation, cell cycle progression and lipid raft formation in lymphoma. This study illustrates the cross-pillar logic targeting both metabolic (SREBP/HMGCR) and signaling (mTORC1) pillars and highlights the importance of anticipating compensatory resistance mechanisms[18].

As further supportive context for this approach, Hillis et al[7] performed a genome-wide Clustered Regularly Interspaced Short Palindromic Repeats/CRISPR-associated protein 9 screen in triple-negative breast cancer and identified cholesterol homeostasis as a collateral vulnerability with AKT inhibition. In that study, pitavastatin synergized with AKT inhibitors in triple-negative breast cancer cells. Furthermore, they demonstrated that the mechanism involves the hampered activation of SREBP-2 (a master regulator of cholesterol and lipogenesis) and impaired cholesterol trafficking. This research highlights a further instance of using synthetic lethality screening to uncover potential cross-pillar vulnerabilities[19].

SREBP AS A CANDIDATE CENTRAL HUB FOR CROSS-PILLAR INTEGRATION

It can be seen from the growing literature that the SREBP transcription factors, namely SREBP1 and SREBP2, appear to serve as candidate nodes that link oncogenic signaling with metabolic reprogramming, which we now know encompasses both lipid and glucose metabolism[5,10,20]. As shown by Huang and Ma[1], the mechanistic axis AMPK-SREBP1 is consistent with this larger picture. The convergence of different oncogenic pathways, such as PI3K/AKT and mTORC1, through SREBP regulation suggests that targeting cholesterol/lipid metabolism in combination with upstream signaling inhibitors may be a relevant therapeutic approach[5-7,21].

CONSTRAINTS AND FUTURE OUTLOOK

Despite Huang and Ma’s study[1] demonstrating important proof-of-concept with the atorvastatin-gefitinib combination, these findings are limited and require further consideration. Initially, two CRC cell lines (SW480/HCT116) and one xenograft model (SW480) were studied, which does not reproduce the heterogeneity of CRC in humans. The molecular diversity of colorectal tumors is characterized by microsatellite instability, CpG island methylator phenotype and consensus molecular subtypes. The synthetic lethal association observed cannot be generalized for the entire population[22,23]. In addition, the in vitro nature of most of the mechanistic insights makes the translational relevance of the AMPK-SREBP1 axis in humans unknown. The study did not analyze off-target effects or the long-term toxicity of the combination regimen, which is important for clinical translation. Evaluation of inter-tumor heterogeneity of the treatment response is hampered by the lack of patient-derived xenograft and organoid models[24,25].

To address these limitations, multi-center validation, more diverse preclinical models and assessment of predictive biomarkers are required[26,27]. Well-designed clinical trials will be needed after sufficient preclinical validation to assess the safety and efficacy of this combination[17,28].

CURRENT CONTROVERSIES AND UNRESOLVED QUESTIONS

Although cross-pillar targeting is conceptually appealing, several controversies and unresolved questions remain. First, the relative contribution of on-target vs off-target effects of statins remains a subject of debate[29-32], because anti-cancer effects may involve HMGCR inhibition as well as cholesterol-independent mechanisms such as immune modulation and protein prenylation inhibition[33-35]. Second, the timing and duration of combination therapy are still inadequately defined[36].

Third, it is critical to assess whether and to what extent the cross-pillar framework can be applied across molecular subtypes of CRC and other cancers. This question is biologically plausible because oncogenic signaling and cancer metabolism are closely connected[37-39], but microsatellite instability, CpG island methylator phenotype and consensus molecular subtypes can affect treatment response in CRC[40,41]. Fourth, the safety profiles of treatment combinations with statins, including drug-drug interactions, effects on muscle and liver function and long-term toxicities, should be assessed in clinical trials[42-45].

DIRECTIONS AND RESEARCH PRIORITIES

To evaluate the cross-pillar targeting framework and move it from concept toward the clinic, multi-center preclinical and translational studies that include diverse CRC models and patient-derived specimens are needed[46]. Patient-derived xenografts and organoids, which are more representative of intratumoral heterogeneity, would provide stronger evidence of the context-dependence and potential applicability of this approach[47].

Furthermore, it is necessary to identify predictive biomarkers that can accurately stratify patients[48]. SREBP expression levels, PI3K pathway activation status, cholesterol synthesis gene signatures, and AMPK activity may serve as candidate biomarkers[49], and retrospective evaluation of available clinical data sets, including The Cancer Genome Atlas and Clinical Proteomic Tumor Analysis Consortium resources, may help define molecular correlates of sensitivity[50,51]. After sufficient preclinical support, prospective phase I/II trials assessing dose escalation, safety, and preliminary efficacy may be considered[52]. Additional studies should systematically examine crosstalk and compensatory mechanisms between signaling pathways and metabolic adaptation[53,54]. Further work should also test whether this framework can inform new therapeutic pairings involving PI3K-, AMPK-, SREBP-, or mitogen-activated protein kinase-related pathways[55-60].

TOWARDS A CONTEXT-DEPENDENT FRAMEWORK FOR RATIONAL THERAPY

According to the study by Huang and Ma[1], the atorvastatin-gefitinib combination represents not only a potentially useful drug combination but also a conceptual starting point for the rational development of synergistic combination therapies. However, this should be viewed as a CRC-centered and context-dependent framework rather than an already broadly established principle in cancer therapy. Evidence from CRC[1,9], lung cancer[3,4,8], lymphoma[6] and breast cancer[7] provides supportive but indirect context for this concept rather than direct validation across tumor types. Future research should test this framework across biologically defined tumor contexts.

CONCLUSION

This opinion review uses a conceptual lens in which Huang and Ma’s findings[1] represent a CRC-centered cross-pillar targeting strategy. The concurrent inhibition of sustained proliferative signaling and metabolic reprogramming, may lead to marked synthetic lethal effects in selected CRC contexts. However, this evidence should be interpreted as convergent but still limited support, not as proof that this model is broadly applicable. Further validation in heterogeneous preclinical models, patient-derived systems, biomarker-defined settings and clinical studies will be important for translation.